Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. GSK plc (NYSE:GSK) is one of the best weight loss drugs on this list.

TheFly reported on June 17 that GSK and Spero Therapeutics announced that the U.S. Food and Drug Administration approved Utebzi for the treatment of complicated urinary tract infections, including pyelonephritis, in adult patients with limited oral treatment alternatives. The approval marked the first oral carbapenem antibiotic authorized for this patient population. The companies noted that the drug was developed through their licensing and collaboration agreement and expect it to become available in the United States by the end of 2026. The approval also strengthened GSK’s expanding anti-infectives portfolio and highlighted the progress of its partnership with Spero Therapeutics.

Copyright: delcreations / 123RF Stock Photo

Additionally, earlier on June 12, GSK plc (NYSE:GSK) announced that momelotinib, a JAK inhibitor marketed as Ojjaara/Omjjara, received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of VEXAS syndrome. The designation supports the development of the therapy for a rare and progressive blood disorder associated with significant rheumatologic and hematologic complications. The condition currently lacks approved treatment options and is linked to a high mortality rate, underscoring the unmet medical need in this patient population.

GSK plc (NYSE:GSK) is a global biopharmaceutical company expanding into obesity and metabolic disease research. Its pipeline focuses on obesity-related conditions, including MASH, while leveraging acquisitions and drug development efforts to explore next-generation weight-loss therapies.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.